[{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Eight Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Eight Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Eight Capital"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ ","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ "},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BMB-101","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BMB-101","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BMB-201","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Bright Minds Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Bright Minds Biosciences"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Asset Management"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bright Minds Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical advancement of the company's lead product BMB-101, which is being evaluated for the treatment of Epilepsy. "

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 04, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Asset Management

                          Deal Size : $35.0 million

                          Deal Type : Private Placement

                          blank

                          02

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy (DEE).

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 21, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The proceeds from the financing will be used to fund the clinical development of the company's lead product, BMB-101, which is being evaluated for the treatment of epilepsy.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 18, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $35.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : BMB-201 is a selective 5-HT2A/2C receptor agonist, small molecule drug candidate, which is currently being evaluated for the treatment of pain.

                          Brand Name : BMB-201

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 16, 2024

                          Lead Product(s) : BMB-201

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The collaboration aims to analyze the data from its first-in-human Phase 1 of BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, for neuropsychiatric disorders and epilepsy.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 16, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : Firefly Neuroscience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy (DEE).

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 12, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsiesand other indications, such as psychosis, addiction, and impulse control disorders.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 08, 2023

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : BMB-101 is a highly selective and potent 5-HT2C agonist, being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 20, 2023

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The Company intends to use the aggregate gross proceeds from the PFW Offering and the Unit Offering to complete the Phase 1 clinical trial for BMB-101 and a regulatory toxicology package and related activities for BMB-202.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 02, 2022

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : $2.0 million

                          Deal Type : Private Placement

                          blank

                          10

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The Company intends to use the aggregate gross proceeds from the PFW Offering and the Unit Offering to complete the Phase 1 clinical trial for BMB-101 and a regulatory toxicology package and related activities for BMB-202.

                          Brand Name : BMB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 28, 2022

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor :

                          Deal Size : $2.0 million

                          Deal Type : Private Placement

                          blank